The patented compound merges the therapeutic power of adamantane and dihydrazide-dihydrazone groups, known for their efficacy in treating Type 2 diabetes, neurological disorders like Parkinson’s and Alzheimer’s, and cancer. The dihydrazide-dihydrazone ability to address anti-diabetes and hypertension gives it an edge over existing treatments.
Overview
Our patented compound contains adamantane and dihydrazide-dihydrazone groups, both of which are known for their medicinal properties, as demonstrated in numerous literature reviews. The compound holds promise in the treatment of several diseases, especially cancer, neurological disorders, and diabetes.
Adamantane Derivatives:
Adamantane Derivatives:Widely recognized for their efficacy in treating neurological conditions, such as Parkinson’s disease and Alzheimer’s disease, adamantane-based compounds are expected to play a pivotal role in the pharmaceutical industry in the near future. According to existing research, adamantane’s ability to mitigate neurological complications associated with Type 2 diabetes further strengthens its therapeutic potential.
Dihydrazide-Dihydrazone Compounds:
Known for their effectiveness against hypertension and diabetes, these compounds also exhibit various other pharmacological activities. The literature highlights the specific benefits of hydrazide/hydrazone derivatives in inhibiting alpha-glucosidase, a key enzyme related to Type 2 diabetes management.
For more details about technology: Click Here
Patent Application No.: : 202221033544
PCT Patent No.: WO2023237924A1